Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.39 |
| ▸ | PKM | P14618 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048678 | 0.83 | PHGDH (0.46) | KMT2AALDH1A1MEN1MAPTLMNA | |
| SCHEMBL4050006 | 0.81 | KDM1A (0.45) | KMT2AALDH1A1MEN1MAPTRAB9A | |
| SCHEMBL4050455 | 0.80 | ALDH1A1 (0.40) | KMT2AALDH1A1PKMGAAMEN1 | |
| SCHEMBL4050956 | 0.79 | PTGS2 (0.46) | KMT2AALDH1A1GAAMEN1MAPT | |
| SCHEMBL4051288 | 0.78 | GRM4 (0.42) | ALDH1A1PKMGAAMAPTMAPK1 | |
| SCHEMBL4050453 | 0.77 | ALDH1A1 (0.41) | KMT2AALDH1A1PKMGAAMAPK1 | |
| SCHEMBL30487906 | 0.75 | LMNA (0.61) | KMT2AALDH1A1PKMGAAMEN1 | |
| SCHEMBL83885 | 0.75 | LMNA (0.61) | KMT2AALDH1A1PKMGAAMEN1 | |
| SCHEMBL4050598 | 0.74 | SMN1; SMN2 (0.53) | KMT2AALDH1A1PKMGAAMAPT | |
| SCHEMBL8715253 | 0.74 | LMNA (0.59) | KMT2AALDH1A1PKMGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| EP-2029584-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007096618-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | RB1, RBBP5, RRM2B | KMT2A 531/4885ALDH1A1 1277/4885PKM 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.